47 results on '"Pagliardini, Thomas"'
Search Results
2. Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome
3. GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation
4. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome
5. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
6. Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas
7. Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation
8. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma
9. Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome
10. Peripheral Blood Stem Cells versus Bone Marrow for T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma
11. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients
12. A Single Center Real World Experience of Allogeneic HSCT of Patients with MDS/CMML in Aged Population
13. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison
14. Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation
15. Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients
16. Prep@Gref: Software Streamlining for the Search for Donors for Hematopoietic Stem Cell Transplantation
17. Autologous Stem Cell Transplant in 2nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience
18. Post-transplant cyclophosphamide versus antithymocyte globulin as GVHD prophylaxis for 10/10 HLA-matched unrelated allogeneic hematopoietic stem cell transplantation.
19. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia
20. Endowing Universal CAR T-cell with Immune-Evasive Properties using TALEN-Gene Editing
21. Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study
22. Higher Grade Cytokine Release Syndrome Is a Predictive Factor for Gvhd in Haploidentical Stem Cell Transplantation with Peripheral Blood Cell
23. Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome
24. Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome
25. High-dimensional mass cytometry analysis of NK cell alterations in Acute Myeloid Leukemia identifies a subgroup with adverse clinical outcome
26. Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy
27. Haplo Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis
28. Greffe allogénique de cellules souches hematopoïétiques utilisant un donneur haploidentique versus non apparenté chez des patients de moins de 60 ans atteints d'hémopathies malignes : une expérience monocentrique de 209 malades
29. Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma
30. Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies
31. CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy
32. Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients
33. Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation
34. Checkpoint Inhibition Before Haploidentical Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma (Hl) Patients is Associated with Higher PFS without Increased Toxicities
35. Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy.
36. CAR-NK: vers une immunothérapie cellulaire prête à l'emploi.
37. Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients
38. Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 + cells
39. Allogeneic Hematopoietic Stem Cell Transplantation for Patients Over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison
40. Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells.
41. Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge
42. 51 - Allogeneic Hematopoietic Stem Cell Transplantation for Patients Over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison
43. Allogeneic Hematopoietic Stem Cell Transplantation for Patients over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison
44. Haploidentical Hematopoietic Stem Cell Allogeneic Transplantation with High Dose Post Transplantation Cyclophosphamide for Patients over 60 Years of Age
45. Autologous Stem Cell Transplant in 2ndLine DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience
46. Thiotepa, Fludarabine and Busulfan conditioning regimen before T-cell replete haploidentical transplantation with post-transplant cyclophosphamide for AML and MDS : a bicentric experience of 109 patients
47. Efficacy and Safety of Donor Lymphocyte Infusions for Patients affected by Advanced Lymphoid Malignancies after Allogeneic Stem Cell Transplantation: A Retrospective Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.